Masayuki Tsuchiya

This inventor holds 49 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents, primarily in Antibody Development. Top assignees: Chugai Seiyaku Kabushiki Kaisha, Chugai Pharmaceutical Co., Ciea International Inc.. Active years: 1998-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masayuki Tsuchiya. Retrieved from https://idiyas.com/inventor/masayuki-tsuchiya

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 49 (Patent Applications = 1)

% Patents Active = 53.1

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 3.8

ph-index = 15

Forward Citations = 1,339(Granted Patents)

Location History:

Gotenba, GB (1998)
Kawachi-Gun, JP (2004)
Gotemba, JP (2003 - 2011)
Shizuoka-ken, JP (2013)
Gotenba, JP (1998 - 2014)
Tokyo, JP (2011 - 2015)
Shizuoka, JP (2000 - 2023)

Company Filing History:

42 out of 987

Chugai Seiyaku Kabushiki Kaisha

patents

3 out of 14

Chugai Pharmaceutical Co.

patents

2 out of 2

Ciea International Inc.

patents

4. 2 out of 3

Pharmalogicals Research Pte. Ltd.

patents

5. 1 out of 1

Chugai Seiyaku Kabushiki

patent

6. 1 out of 172

Kabushiki Kaisha F. C. C.

patents

7. 3 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2023

Loading Chart...

Areas of Expertise:

Wet Friction Plate

Multi-Plate Clutch

Anti-CD47 Antibody

Cell Growth Inhibitors

Anti-Ganglioside Antibodies

Polypeptide Inducing Apoptosis

Gene Encoding HM1.24

Fucose Transporter

HCV-Derived RNA Polymerase

Signal Transduction Inhibition

Natural Human Antibody

Mannosyltransferase Polypeptides

49 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11639741 - Wet friction plate and wet multi-plate clutch device (2023-05-02),

2. 8946386 - Proteins expressed in NK cells (2015-02-03),

3. 8759025 - Humanized anti-CD47 antibody (2014-06-24),

4. 8586039 - Degraded TPO agonist antibody (2013-11-19),

5. 8343761 - Methods of generating and using antibody-producing cells (2013-01-01),

6. 8263077 - Cell growth inhibitors containing anti-glypican 3 antibody (2012-09-11),

7. 8257703 - Anti-ganglioside antibodies and compositions (2012-09-04),

8. 8158385 - Cell death-inducing agent (2012-04-17),

9. 8105799 - Methods of screening compounds inhibiting signal transduction through inflammatory cytokines (2012-01-31),

10. 8101719 - Humanized anti-CD47 antibody (2012-01-24),

11. 8034903 - Degraded TPO agonist antibody (2011-10-11),

12. 8008076 - Method of producing a nucleic acid encoding an antibody (2011-08-30),

13. 8008073 - Anti-Mpl antibodies (2011-08-30),

14. 7993642 - Anti-MPL antibodies (2011-08-09),

15. 7892543 - Reshaped human anti-HM 1.24 antibody (2011-02-22),

Title: The Innovative Journey of Masayuki Tsuchiya

Introduction:

Masayuki Tsuchiya, a distinguished inventor hailing from Shizuoka, Japan, has made significant contributions to the field of technology through his groundbreaking innovations and patents.

Latest Patents:

Tsuchiya's recent patents include advancements in robotics, artificial intelligence, and sustainable energy solutions, showcasing his versatility and forward-thinking approach to invention.

Career Highlights:

With a career spanning over two decades, Masayuki Tsuchiya has established himself as a pioneer in the tech industry, with a keen focus on developing cutting-edge solutions that address real-world challenges.

Collaborations:

Throughout his career, Tsuchiya has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life, fostering a culture of innovation and knowledge-sharing within the industry.

Conclusion:

Masayuki Tsuchiya's relentless pursuit of innovation and his passion for creating a positive impact on society through his inventions truly set him apart as a visionary inventor in the ever-evolving world of technology.

Profile summary based on public USPTO records.